Novanta Inc. Common Stock
NOVT
$145.52
-0.29%
Novanta Inc. is a technology company that supplies core solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It operates through two segments: Automation Enabling Technologies, which provides laser beam steering, scanning solutions, laser sources, and robotic motion technologies, and Medical Solutions, which offers medical-grade technologies like insufflators and endoscopic pumps. As a niche player in precision technologies, Novanta holds a strong position in high-value, specialized markets. The current investor narrative centers on the company's recovery from a period of underperformance, driven by institutional confidence and a recent rally, while debates persist over its rich valuation and the implications of insider selling.…
NOVT
Novanta Inc. Common Stock
$145.52
Related headlines
NOVT 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Novanta Inc. Common Stock's 12-month outlook, with a consensus price target around $194.50 and implied upside of +33.7% versus the current price.
Average Target
$194.50
0 analysts
Implied Upside
+33.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$194 - $195
Analyst target range
The narrow target range ($170-$180) indicates relatively high conviction among the few analysts covering the stock, though the limited coverage itself suggests a smaller-cap or less-followed name, which can lead to higher volatility and less efficient price discovery. The high target of $180 likely assumes continued growth in the medical and industrial segments, while the low target of $170 may factor in potential margin pressures or market competition. With only 2 analysts, the consensus should be interpreted with caution, as it may not fully reflect market sentiment.
NOVT Technical Analysis
Novanta's stock is in a strong uptrend, with a 1-year price change of +43.59%, significantly outperforming the S&P 500's +21.46% over the same period. The current price of $163.32 sits at 87.5% of the 52-week range (between $98.27 and $176.19), indicating the stock is trading near its highs, reflecting robust momentum but also potential overextension. The stock has recovered sharply from its 52-week low, showing a strong recovery trend.
Beta
1.68
1.68x market volatility
Max Drawdown
-27.0%
Largest decline past year
52-Week Range
$98-$176
Price range past year
Annual Return
+26.4%
Cumulative gain past year
| Period | NOVT Return | S&P 500 |
|---|---|---|
| 1m | -0.2% | +1.9% |
| 3m | -8.9% | +2.3% |
| 6m | -0.3% | +10.6% |
| 1y | +26.4% | +19.5% |
| ytd | +30.9% | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NOVT Fundamental Analysis
Revenue growth has been robust, with the most recent quarterly revenue estimated at $1.125 billion (annualized), reflecting a strong growth trajectory. The company's gross margin stands at 41.59%, indicating healthy profitability, while operating margin is 11.90%, showing efficient cost management. Net income is positive, with an EPS of $0.012, and the net margin is 5.49%, demonstrating the company's ability to convert revenue into profit.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NOVT Overvalued?
Given that Novanta has positive net income, the PE ratio is the primary valuation metric. The trailing PE is 80.95x, while the forward PE is 39.42x, indicating the market expects significant earnings growth. The PS ratio is 4.44x, and the EV/Sales is 5.56x, both above industry averages, suggesting a premium valuation. The PEG ratio is negative (-4.65), which is unusual and may indicate expected earnings declines or data inconsistencies.
PE
80.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
28.2x
Enterprise Value Multiple